채용
Essential Functions
- Prepare monthly rolling forecast
- Monitor and review variance between actual results, forecast, and budget/backlog for IQVIA Biotech.
- Coordinate with Project Leadership team/Project finance manager when required to address variance
- Analyse monthly business performance (by projects, region, function etc.) during revenue recognition weeks
- Provide management reports with insights and actionable recommendations
- Track and monitor key performance indicators (Utilization, Rev/FTE, etc.)
- Partner with BU management team to provide financial support including monthly financial review (1-1 sessions)
- Support department in understand the financial impact of decisions
- Conduct scenario planning and sensitivity analysis and support long-term strategic planning (FTE planning)
- Provide financial insights for special request (e.g. justification etc.) Prepare monthly revenue allocations and journals
- Assist with preparation of the monthly financial review deck for the region
- Develop and maintain financial templates Investigate and resolve accounting posting discrepancies
Requirements:
- Bachelor’s degree in accounting or relevant discipline
- At least 5 years of relevant experience in financial planning & analysis (FP&A), business finance, or management reporting, preferably in a project-based or matrix organization.
- Hands-on experience preparing and managing monthly rolling forecasts, budgets, and variance analysis.
- Experience with large ERP systems/ Peoplesoft preferred
- Knowledge of Microsoft Office applications
- Strong analytical and numeracy skills
- Effective verbal and written communication skills Professional qualification (e.g. ACCA, CPA, CA, CFA) is an advantage but not mandatory
IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. We create intelligent connections to accelerate the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. Learn more at https://jobs.iqvia.com
IQVIA is committed to integrity in our hiring process and maintains a zero tolerance policy for candidate fraud. All information and credentials submitted in your application must be truthful and complete. Any false statements, misrepresentations, or material omissions during the recruitment process will result in immediate disqualification of your application, or termination of employment if discovered later, in accordance with applicable law. We appreciate your honesty and professionalism.
총 조회수
0
총 지원 클릭 수
0
모의 지원자 수
0
스크랩
0
비슷한 채용공고

Director, SEA Tax
Applied Materials · Singapore, Singapore

Chief of Risk
Revolut · Singapore

Wealth Business Execution Specialist - AIMS (Vice President)
Citigroup · singapore

Asset Management - Equity Trading - Vice President
JPMorgan Chase · Singapore, Singapore, SG

Cluster Finance Director – HK, SG, TWN, INDO
Abbott · Singapore
IQVIA 소개

IQVIA
PublicIQVIA Holdings, Inc. is an American company based in Durham, North Carolina, focused on health information technology and clinical research.
10,001+
직원 수
Durham
본사 위치
$17B
기업 가치
리뷰
3.6
10개 리뷰
워라밸
3.8
보상
2.5
문화
4.0
커리어
3.2
경 영진
2.8
65%
친구에게 추천
장점
Good work-life balance
Supportive team and collaborative environment
Good benefits and flexible hours
단점
Compensation below industry standards
High workload and overwhelming at times
Management communication and organization issues
연봉 정보
45개 데이터
Mid/L4
Mid/L4 · ANALYST
2개 리포트
$97,500
총 연봉
기본급
$102,667
주식
-
보너스
-
$97,500
$97,500
면접 경험
3개 면접
난이도
3.0
/ 5
소요 기간
14-28주
경험
긍정 0%
보통 33%
부정 67%
면접 과정
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Technical Manager Interview
5
Executive/GM Interview
6
Offer
자주 나오는 질문
Behavioral/STAR
Case Study
Technical Knowledge
Past Experience
Culture Fit
뉴스 & 버즈
IQVIA Shareholders Approve New 2026 Incentive Plan - TipRanks
TipRanks
News
·
5d ago
IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
MarketWatch
News
·
5d ago
The Oral GLP-1 Tracker: Lilly's launch of Foundayo lags, boosting Novo's shares - Fierce Pharma
Fierce Pharma
News
·
5d ago
The outlook for obesity from 2026 to 2030 - IQVIA
IQVIA
News
·
1w ago